Below is a list with tagged columns and company profiles.
Latest Reports Kalbe Farma
Kalbe Farma, Indonesia's largest pharmaceutical company, is set to start marketing its erythropoietin product (also known as EPO) domestically. Starting from mid-2018 Kalbe Farma will produce EPO, one of the raw materials for the production of medicines to treat cancer and kidney disease. The pharmaceutical company will become the first publicly listed company on the Indonesia Stock Exchange that produces EPO.
Indonesia's largest pharmaceutical company, Kalbe Farma, felt the impact of macroeconomic headwinds. The company, one of the largest public pharmaceutical companies in Southeast Asia, today announced its indicative performance (unaudited) for the year 2015. While its net sales grew 3 percent year-on-year (y/y) to IDR 17.4 trillion (approx. USD $1.3 billion), the company's net income fell 4.3 percent (y/y) to IDR 1.98 trillion (approx. USD $147 million). Kalbe Farma's performance in 2015 was plagued by weaker purchasing power in Indonesia and the depreciated rupiah exchange rate.
In one of the next economic stimulus packages of the Indonesian government the focus will be on increasing domestic production of raw materials for medicines and medical devices. Currently, these industries are still highly dependent on imports of raw materials. It is estimated that around 90 percent of raw/basic materials for medicines and medical devices need to be imported from abroad and therefore cause additional pressure on Indonesia's balance of payments.
On Tuesday (24/03), Indonesian hospital operator Mitra Keluarga Karyasehat became the second company to list on the Indonesia Stock Exchange (IDX) in 2015. It turned out to be a highly successful initial public offering (IPO) as the company’s shares surged 24.7 percent on its trading debut, reflecting investors’ solid confidence in healthcare stocks. Mitra Keluarga, subsidiary of pharmaceutical company Kalbe Farma, raised IDR 4.4 trillion (USD $341 million), hence constituting the largest IPO since Garuda Indonesia’s IPO in 2011.
Shares of Kalbe Farma, Indonesia’s largest pharmaceutical company, have been under pressure over the past couple of days due to the deaths of two hospital patients after they had taken a medicine manufactured by Kalbe Farma. According to the Indonesian Pharmacy Association (GP Farmasi Indonesia) Buvanest Spinal, an anesthetic, was wrongly packaged and hence did not contain bupivacaine but instead tranexamic acid, which aims to stop or reduce heavy bleeding (usually used during surgery).
What were the important corporate news headlines from Indonesia on Thursday 14 August 2014? Below Indonesia Investments presents the daily market roundup. This includes the following companies and topics: XL Axiata, Telekomunikasi Indonesia (Telkom), Kalbe Farma, Telekomunikasi Seluler, Telkomsel, Golden Agri Resources, Matahari Putra Prima, Loop card, Lippo Group, Hypermarts, the Industry Ministry of Indonesia, technology businesses, and the ASEAN Economic Community (AEC).
Indonesia Investments has updated the company profile of PT Kalbe Farma Tbk. Kalbe Farma is the largest listed pharmaceutical company in Indonesia and Southeast Asia (listed on the Indonesia Stock Exchange/IDX). The company’s main business focus rests on four divisions: prescription pharmaceuticals, consumer health products, nutritionals as well as distribution & logistics. Its a leading provider of “comprehensive healthcare solutions”, from pharmaceuticals, nutrition, health foods and beverages to medical devices, including primary healthcare service.
On Thursday (08/05/2014), the winners of the Investor Awards Best Listed Companies 2014, organized by Investor magazine, were announced. Five companies earned the predicate Top Performing Listed Companies 2014 due to the companies sound fundamental and technical performance (over the year 2013). These were Bank Rakyat Indonesia, Kalbe Farma, Tower Bersama Infrastructure, Pembangunan Perumahan, and Lippo Cikarang. These five companies were selected from a total of 493 listed companies on the Indonesia Stock Exchange (IDX).
Latest Columns Kalbe Farma
Companies active in the pharmaceutical industry of Indonesia need to find strategies to overcome sharp rupiah depreciation. Indonesia’s pharmaceutical industry is still - to a large extent - dependent on the import of raw materials, hence a weakening rupiah raises the costs of imports thus eroding profit margins. Since May 2013, when the US Federal Reserve started to hint at monetary tightening, the US dollar has experienced bullish momentum. Between the May 2013 and July 2015, the rupiah depreciated around 37 percent against the US dollar.
Mitra Keluarga Karyasehat, a leading Indonesian hospital operator and subsidiary of the Kalbe Group, plans to raise about IDR 4.2 trillion (USD $328 million) in an initial public offering (IPO) on the Indonesia Stock Exchange (IDX) in March 2015. The company plans to offer up to 261.9 million shares, or 18 percent of its enlarged equity, to the public. Five percent of this total constitute new shares, while 13 percent are shares divested by private equity firm Lion Investment Partners.
The benchmark stock index of Indonesia (Jakarta Composite Index, abbreviated IHSG) declined 0.92 percent to 5,136.86 points on the last trading day of the week. Seven of the ten sectorial indices fell, led by the finance sector (-1.66 percent), followed by consumer goods (-1.50 percent) and manufacturing (-1.34 percent). The main reason for this poor performance is that investors are again looking at the true fundamentals of the Indonesian economy instead of optimism about Joko Widodo becoming Indonesia’s seventh president.
